Published February 5, 2018
Dhaval K. Shah, PhD '10, has joined the Science Advisory Board at Applied BioMath, an industry-leader in applying mechanistic modeling, simulation, and analysis to drug research and development.
Shah is an Assistant Professor of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics, and is funded by the National Institutes of Health, The Center for Protein Therapeutics at the University at Buffalo, and several pharmaceutical companies. His lab uses the principles of pharmacokinetics and pharmacodynamics (PK/PD) modeling and simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineering antibodies, antibody-drug conjugates, multi-specific proteins, immuno-oncology agents, and engineered T cells.
During his time at UB, Shah has pioneered the development of translational systems pharmacokinetic models for protein therapeutics, and also developed experimental techniques (e.g. microdialysis and imaging) to support the development of these models for challenging tissues like solid tumors, eye and brain.
Shah brings his PK/PD modeling and simulation expertise to Applied BioMath, known for its Model-Aided Drug Invention (MADI) approach to drug research and development. MADI leverages mechanistic PK/PD and systems pharmacology, which quantitatively integrates knowledge about therapeutics with an understanding of mechanism of action in the context of human disease mechanisms. Shah is the most recent of several key opinion leader to join Applied BioMath's Science Advisory Board, joining Joseph Loscalzo, MD & PhD, Werner Meir, Bruce Tidor, PhD, Mike Yaffe, MD & PhD, and Douglas A. Lauffenburger, PhD, on the board.
"We are excited to welcome Dr. Shah to our Science Advisory Board," said Joshua Apgar PhD, Co-Founder and CSO at Applied BioMath. "His leadership in extending the state of the art for PBPK modeling and simulation for biotheraputics makes him an invaluable resource as we [Applied BioMath] continue to expand our services in various therapeutic areas."
"I have known Dr. Shah for almost 10 years, and have always been very impressed by his science, thoughtfulness, and kindness. I am very excited to see him join our SAB," said John Burke PhD, Co-founder and CEO at Applied BioMath.
Prior to his current role, Shah served as Principal Scientist in the Translational Research - Modeling and Simulation group at Pfizer, Inc. Shah earned his PhD in Pharmaceutical Sciences from UB in 2010.